NASDAQ : WALD

Waldencast plc — News

$1.7 USD

-$0.03 (-1.73%)

Volume
598.25K
Average Volume
649.55K
Market Capitalization
$201.01M
P/E Ratio
-0.84
Dividend Yield
0.00%
Price Target
$3.00
Year High
$3.22
Year Low
$0.72
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.70
Source Headline
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint

LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses), marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.

globenewswire.com - 2026-07-30 16:30:00

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (“HA”) gel, the latest addition to the Obagi® injectable portfolio under the Obagi Medical brand. This approval builds on the launch of Obagi® saypha® MagIQ™ and accelerates Obagi Medical's strategy to establish Obagi as a comprehensive leader at the intersection of advanced skincare and medical aesthetics.

globenewswire.com - 2026-06-15 09:00:00

Waldencast Announces Sale of Obagi Medical to Bridgepoint

LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.

globenewswire.com - 2026-06-01 06:59:00

Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting

Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success

globenewswire.com - 2026-05-15 08:13:00

Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience

A multi-city pop-up introducing consumers to the future of skincare and longevity innovation A multi-city pop-up introducing consumers to the future of skincare and longevity innovation

globenewswire.com - 2026-05-14 08:15:00

Get WALD Insider Trade Alerts

WALD Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$3.00

1 analysts

Last Year

$2.88

4 analysts

All Time

$6.30

10 analysts

WALD Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-06-02 Canaccord Genuity Maintain Buy Buy
2026-03-16 Telsey Advisory Group Maintain Market Perform Market Perform
2026-03-16 Canaccord Genuity Maintain Buy Buy